Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Baricitinib

First oral JAK inhibitor approved for the treatment of atopic dermatitis

    • Allergology and clinical immunology
    • Dermatology and venereology
    • Market & Medicine
    • RX
  • 3 minute read

The use of small molecule drugs for the treatment of atopic dermatitis has been investigated for some time. With the approval of the Janus kinase (JAK) inhibitor baricitinib, a new oral treatment alternative is now available for patients with moderate to severe atopic dermatitis.

Swissmedic granted marketing authorization to the Janus kinase (JAK) inhibitor baricitinib (Olumiant®) in February 2021 for the treatment of adult patients with moderate to severe atopic dermatitis. This is the first oral JAK inhibitor available in Switzerland for the treatment of atopic dermatitis [1] (box). Atopic dermatitis is one of the most common chronic inflammatory skin diseases and is associated with a significantly reduced quality of life, particularly in severe cases [2]. Comorbidities are common: itching can lead to sleep disturbances and the risk for depression and anxiety disorders is greatly increased compared to skin healthy individuals [4].

 

 

Rapid relief of itching and effective reduction of skin lesions

The BREEZE-AD7 trial evaluated efficacy and tolerability of baricitinib in combination with topical corticosteroids (TCS) of light or moderate class [6]. Already after four weeks, a significantly higher proportion of the group treated with baricitinib 4 mg and TCS showed a reduction of itch by ≥4 points on the pruritus NRS, corresponding to a clinically relevant relief (p<0.001) [6]. At week 16, 44% of patients receiving the standard dose of baricitinib and TCS achieved clinically relevant relief of pruritus, more than twice the proportion receiving placebo and TCS (p<0.001) [6]. Visible eczematous lesions in particular can be very distressing for patients with atopic dermatitis. In a survey of patients with severe atopic dermatitis in 8 countries, 82% reported that they were concerned about their appearance [3]. In the BREEZE-AD7 study, baricitinib also proved highly effective in terms of EASI75 response, which corresponds to a clearly visible relief of skin symptoms. At week 16, 48% of patients achieved an EASI75 response with baricitinib and TCS, more than twice as many as with placebo and TCS (p<0.001) [6].

 

 

Patient-friendly dosage form and good tolerability

Baricitinib is very easy to use: one tablet daily, regardless of meals or time of day. Since elimination is predominantly renal, there are few clinically relevant drug-drug interactions. Moreover, thanks to a short half-life, baricitinib is well controllable and can be adjusted to a dose of 2 mg if necessary [1]. Comprehensive data on the safety and tolerability of baricitinib in atopic dermatitis are available from a pooled safety analysis of 8 randomized clinical trials involving 2531 patients and 2247 patient-years [7]. This showed an incidence of serious infections, opportunistic infections, and conjunctival complications comparable to placebo. The most common adverse reactions reported were nasopharyngitis and headache, as well as elevation of creatine phosphokinases and diarrhea. However, these did not usually lead to treatment discontinuation [7]. Even in the rheumatoid arthritis indication, where baricitinib has been used for some time, the favorable safety profile of baricitinib observed in clinical trials for the treatment of RA proved to be consistent for up to 8.4 years, according to the results of a recent integrated safety analysis [5].

Source: Eli Lilly

 

Literature:

  1. Professional information Olumiant®, www.swissmedicinfo.ch, (last accessed 08.04.2021)
  2. Silverberg JI, et al: Ann Allergy Asthma Immunol 2018; 12(3): 340-347 .
  3. Guttman-Yassky E, et al: J Am Acad Dermatol. 2019; 80: 913-921.e9.
  4. Ronnstad ATM, et al: JAAD 2018; 79: 448-456.
  5. Genovese MD, et al: Ann Rheum Dis 2020; 79 (Suppl. 1): 638, Abstract: FRI0123
  6. Reich K, et al: JAMA Dermatol 2020; 156(12): 1333-1343.
  7. Bieber T, et al: J Eur Acad Dermatol Venereol 2020; doi: 10.1111/jdv.16948

 

DERMATOLOGY PRACTICE 2021; 31(2): 30

Autoren
  • Mirjam Peter, M.Sc.
Publikation
  • DERMATOLOGIE PRAXIS
Related Topics
  • baricitinib
  • JAK Inhibitor
Previous Article
  • Swiss Association against Osteoporosis (SVGO)

Toolbox for osteoporosis management: update of recommendations.

  • Education
  • General Internal Medicine
  • Geriatrics
  • Orthopedics
  • Prevention and health care
  • RX
View Post
Next Article
  • Early summer meningoencephalitis (TBE)

Do not miss tick vaccination

  • Education
  • General Internal Medicine
  • Infectiology
  • Prevention and health care
  • RX
View Post
You May Also Like
View Post
  • 6 min
  • Case Report

Breast cancer metastases in the bladder

    • Cases
    • Education
    • Gynecology
    • Oncology
    • RX
    • Urology
View Post
  • 11 min
  • Findings from the ALS Symposium 2024 in Montreal

Current and future approaches in the treatment of amyotrophic lateral sclerosis (ALS)

    • Congress Reports
    • Interviews
    • Neurology
    • RX
    • Studies
View Post
  • 8 min
  • Efficacy, mechanism of action and clinical effects

Garlic and high blood pressure

    • Cardiology
    • Education
    • General Internal Medicine
    • Pharmaceutical medicine
    • Phytotherapy
    • RX
    • Studies
View Post
  • 7 min
  • Moderate to severe chronic hand eczema

Delgocitinib cream – first topical pan-JAK inhibitor approved in Switzerland

    • Allergology and clinical immunology
    • Dermatology and venereology
    • Education
    • Infectiology
    • Market & Medicine
    • Pharmacology and toxicology
    • RX
View Post
  • 9 min
  • Wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CA)

Diagnosis at an early stage, prognostic classifications and outlook

    • Cardiology
    • Education
    • RX
    • Studies
View Post
  • 4 min
  • Case report: Drug-induced hepatitis

Rare side effect of tirzepatide therapy

    • Cases
    • Education
    • Endocrinology and Diabetology
    • Gastroenterology and Hepatology
    • Pharmacology and toxicology
    • RX
    • Studies
View Post
  • 4 min
  • Plea for sex-specific neurology

Migraine in men: underdiagnosed, underestimated, under-researched

    • Education
    • Neurology
    • RX
    • Studies
View Post
  • 4 min
  • Prurigo nodularis

Retrospective analyses of large data sets from everyday practice

    • Allergology and clinical immunology
    • Congress Reports
    • Dermatology and venereology
    • RX
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
  • Dermatology News

    Zum Thema
Top CME content
  • 1
    Patience, knowledge and persistence in therapy
  • 2
    Sarcopenia and malnutrition in the context of pneumological rehabilitation
  • 3
    Medical and psychosocial perspectives
  • 4
    New nomenclature for non-alcoholic fatty liver disease
  • 5
    Examinations and considerations before therapy

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.